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MODIFYING DRUGS ARE USED IN THE TREATMENT OF 
RHEUMATOID ARTHRITIS 
Esther Mantel 
INTRODUCTION 
Rheumatoid arthritis is a long-term disease that leads to chronic inflammation 
of the joints and the surrounding tissue. Effects of the inflammation are pain and 
destruction of the bone and cartilage, which leads to severe disability and, possibly, 
shorter life expectancy. That is why early diagnosis and aggressive treatment is a 
fundamental strategy to stop the progression of the disease and suppress the 
inflammation before the damage is irreversible.  
In an attempt to avoid invasive treatments like arthroscopies and surgeries, the 
orthopedist’s first choice of non-pharmacological treatments includes physical and 
occupation therapies. Pharmaceutical treatments such as non-steroidal anti-
inflammatory drugs (NSAIDs) and non-opioid analgesics (pain medication such as 
acetaminophen and aspirin) work on reducing the inflammation caused by rheumatoid 
arthritis, which often results in pain relief. Glucocorticoids, a class of steroid 
hormones, also possess anti-inflammatory effects and were once considered the most 
powerful treatment of inflammatory arthritis, but their use was virtually abandoned 
due to their association with toxicity; they are only used nowadays in controlling acute 
flare-ups joint disease. While these therapeutic strategies reduce inflammation and 
pain caused by rheumatoid arthritis, they are not that beneficial in slowing down the 
joint and bone damage and the progression of the disease. Rheumatologists didn’t 
realize that while the pain was being covered by the medications and anti-
inflammatory drugs, the inflammation and pannus (an abnormal layer of tissue) were 
continuing to cultivate inside the patients joints and articular tissue. For this reason, a 
new and very important group of agents called disease modifying anti-rheumatic 
drugs, or DMARDs, have become a major interest as a potential new therapy in the 
treatment of rheumatoid arthritis.  
While most treatments focus on reducing the inflammation already present in 
the bone tissue and joints, DMARDs work on slowing down occurring bone damage 
and the progression of the disease by actually modifying the disease itself (Katzung 
2001). They are different than other rheumatoid arthritis treatments because they 
work by suppressing the underlying factors that result in synovitis, tissue reactivity, 
erosions, ligament and tendon laxity, subluxations and other complications caused by 
rheumatoid arthritis (Johnson 2011). Since there is no presently known cure for 
rheumatoid arthritis, a lot of research is being done in finding a treatment that will stop 
or at least slow the progression of the bone damage caused by the disease, so that the 
patient can be in remission for a long period of time. 
DISCUSSION 
Rheumatoid arthritis is an autoimmune disease that affects the synovia of joints 
and, eventually, the healthy surrounding tissue and bone, resulting in symmetric and 
erosive polyarthritis. According to Shah and Clair (2011), rheumatoid arthritis affects 
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approximately 0.5-1% of the adult population worldwide. The ratio of rheumatoid-
arthritis-affected women to rheumatoid-arthritis-affected men at premenopausal age is 
4:1 while the same ratio at postmenopausal age is 1:1; this is attributed to the role that 
estrogen has in stimulating tumor necrosis factor-#, a major cytokine in the rheumatoid 
arthritis pathogenesis (Shah and Clair 2011). The exact etiology of rheumatoid 
arthritis is still unknown.  It is known, however, that genetics plays some role in 
development and severity in certain patients. It remains a matter of debate whether the 
trigger of the disease is an exogenous infectious agent, a break in immune tolerance 
leading to classical autoimmunity, or simply random proceedings that accumulate with 
age (Klippel 2001). 
While the auto-antigen that triggers rheumatoid arthritis has not been identified 
yet, the progression and evolution of the disease can be blamed on immune cells and 
mediators that contribute to the inflammation response that occurs. The process of 
how inflammation and erosion develop in synovial tissue and periarticular bone has 
been studied and researched in patients with rheumatoid arthritis.  The primary agents 
involved in the immune response in rheumatoid arthritis patients are T-cells, which 
mainly function in stimulating other cells in the joint to produce and secrete cytokines. 
The most important cytokines involved in rheumatoid arthritis are tumor necrosis 
factor (TNF) and interleukin-1 (IL-1), both produced by macrophages and synovial 
lining cells that were activated by the T-cells in the joints. Once released, TNF and IL-
1 stimulate the synovial cells to proliferate and produce factors contributing to the 
destruction of cartilage, such as inflammatory mediators and matrix 
metalloproteinases, which are endopeptidases. Eventually, bone destruction is caused 
by osteoclasts activated by a TNF ligand called RANKL (Receptor activator of 
nuclear factor kappa-B ligand), which is produced by T-cells and synovial fibroblasts. 
As the hyperplastic and hypertrophy synovium grows over the articular surface, 
pannus develops, which stimulates the resorption of surrounding cartilage (Kumar et 
al. 2005). 
In addition to T-cells acting up, activated B-cells produce inflammatory-
contributing autoantibodies. Some rheumatoid arthritis patients possessor develop 
rheumatoid factors, auto-antibodies that bind to the Fc fragment of Immunoglobulin G 
to form immune complexes that lead to the recruitment of polymorphonuclear 
leukocytes, further exacerbating the ongoing inflammation. The increasing pannus and 
inflamed synovium that spread over the articular cartilage produce large amounts of 
degradative enzymes (e.g. collagenase and stromelysin) that assist in irreversible 
cartilage destruction and subchondral bone erosion (Heaverstock and Jorizzo 2008).   
Since it is a systemic disease, rheumatoid arthritis can affect internal organs as 
well, eventually leading to early death if left untreated. Rheumatoid arthritis typically 
affects joints of the hands and feet first, but can spring up in larger joints at any time. 
One of the essential factors of diagnosing rheumatoid arthritis is stiffness and soreness 
in the mornings after an extended lack of movement. Other clinical findings of 
rheumatoid arthritis are morning pain and swelling in areas such as the phalanges and 
on the balls of the feet. Routine morning activities, such as brushing ones teeth or hair, 
might become difficult due to the clinical manifestations. If left untreated, the disease 
will progress and result in increasing pain, swelling and stiffness caused by the 
destruction of the joints and healthy bones. Figure 1 shows irreversible bone and 
cartilage loss due to untreated rheumatoid arthritis. 
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DISEASE MODIFYING ANTI-RHEUMATOID DRUGS (DMARDS) 
DMARDs are a class of drugs that 
include a diverse group of non-biological and 
biological agents. Although both work on 
suppressing the underlying cause of the 
inflammation in the disease, biological 
DMARDs are protein therapeutics that are 
designed mainly to target cytokines and cell-
surface molecules that promote the 
inflammation response (Shah and Clair 2011). 
It may take 6 weeks to 6 months for the effects 
of the disease-modifying therapies to become 
evident since they are slow acting. It is 
necessary to start the use of DMARDs very 
early in the progression of the disease, since 
they work by slowing the progression and not 
reversing the damage already done. A large 
number of rheumatoid arthritis patients can 
reach remission or at least a low disease 
activity with the use of a single non-biological 
DMARD. However, for those patients with 
moderate or high disease activity or for those 
who failed to respond to a single agent due to 
prolonged disease duration, combinations of 
non-biological DMARDs are used.  
Clinicians realized inadequate response 
was being achieved by patients being treated 
with monotherapy DMARDs, and a more 
aggressive treatment with DMARDs was 
essential for improving rheumatoid arthritis 
symptoms and slowing the progression of the 
disease. The use of biological DMARDs is 
reserved for those who indicate poor prognosis of the disease and do not respond to 
non-biological DMARDs treatment. Many patients who don’t achieve sufficient 
results from either non-biological or biological DMARDS have treatment plans that 
include combining a synthetic DMARD with a biological DMARD in order to reach 
optimal responses from both agent types. DMARD agents are also commonly used in 
combination with non-steroidal anti-inflammatory drugs to reduce present 
inflammation and relieve pain. 
Figure 1: 
Interphalangeal joint abnormalities. 
Osseous erosions are evident at the radial 
and ulnar aspects of the PIP joint of the 
second finger (arrows). Soft-tissue 
swelling and loss of interosseous space are 
additional findings. Marginal erosion is 
also seen on the middle phalanx at the 
distal interphalangeal joint (open arrow) . 
Source: Kountz and Von Feldt 2007  
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Figure 2: The three major rheumatoid 
arthritis therapies.  
Source: 
http://stg.jfponline.com/ccp_article.asp?a=1&r
ef=5610ACCP_Supplement5#5610ACCP_Su
pplement5-fig7 
Rheumatologists are trying to achieve 
early and sustained suppression of the disease 
activity with DMARDs. They believe that 
early detection of the disease and treatment 
with DMARDs might negate the need for 
NSAIDs and corticosteroids. Each rheumatoid 
arthritis patient’s treatment is personalized, 
taking into account the severity of the disease 
and the potential adverse effects of the drugs. 
Since toxicity is a major concern with 
DMARDs, the effects of the drugs must be 
closely monitored, which can cost as much as 
the drug itself (Johnson 2011). Therefore, a 
large amount of effort and research is being 
put in to find the right combination of 
DMARDs that will work best on slowing the 
onset of the disease with reduction of the 
inconvenience of high costs and close 
monitoring. The latest research being done on 
the productivity and effectiveness of single, 
dual, and triple combination of synthetic 
DMARDs and biological DMARDs will be 
discussed in this paper, along with the safety 
monitoring that is necessary with the use of 
these drugs.   
It is important to understanding the mechanism of action of each individual 
drug, because DMARDs work by modifying the disease through inhibiting specific 
parts and pathways of the inflammatory response that occurs in rheumatoid arthritis. 
Knowing the mechanism also helps researchers decide which combination of drugs 
might work well together and which ones to experiment with, resulting in the finding 
of the most productive and effective treatment for the broadest variety of people.  
COMMONLY USED SYNTHETIC DMARDS 
Methotrexate, an analog of folic acid and of aminopterin, is the most commonly 
prescribed DMARD against rheumatoid arthritis in the United States and is usually 
the initial choice when using disease-modifying drugs in rheumatoid arthritis 
treatment.  While its mechanism of action when used at a low dose in rheumatic 
diseases is unclear, it may relate to the polyglutamates metabolized from the 
methotrexate that cause extracellular adenosine to be released, which has anti-
inflammatory and immunotherapy properties (Imboden et al. 2007). According to two 
meta-analyses, methotrexate has the best efficacy/toxicity ratio.  
The most important action shown in studies of methotrexate against 
rheumatoid arthritis is its effects in increasing adenosine (anti-inflammatory agent) 
levels, lowering the pro-inflammatory cytokine levels, and increasing the anti-
inflammatory cytokine levels (Swierkot and Szechinski 2006). Intensive treatment and 
observation while taking methotrexate is recommended in order to attain the most 
benefit from the drug. While patients tend to remain on methotrexate longer than any 
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other DMARD because of better clinical responses and less toxicity, a significant 
number of patients do not achieve premium control over the disease when taking the 
drug alone. As a result, methotrexate can either be used as a monotherapy or in 
combination with other synthetic DMARDs or anti-tumor necrosis factor agents, a 
class of biological DMARDs (Imboden et al.2007). 
A study was done in Japan to evaluate the effectiveness of the government 
recommended 8mg/week dose of methotrexate given to people with rheumatoid 
arthritis. One hundred seventy-six patients with active rheumatoid arthritis at Konan 
Kakagowa Hospital and Kobe University Hospital participated in the study. The 
effects of methotrexate were evaluated by the American College of Rheumatology 
(ACR) core set, which showed maintained improvements in the clinical signs and 
symptoms of rheumatoid arthritis for 24 months. However, according to European 
League Against Rheumatism (EULAR) response criteria, 63.5% of the patients were 
found nonresponsive at 24 months from the methotrexate therapy. Despite the 
treatment, x-rays showed the progression of joint destruction. This study is important 
because it verifies as mentioned before that many patients do not achieve sufficient 
disease control when using methotrexate as a monotherapy (Hashiramoto et al. 2009). 
Most combination therapies involve using another DMARD with methotrexate, to 
enhance the methotrexate clinical response. 
Leflunomide is another very important synthetic DMARD that is widely used. 
Once administered, leflunomide is well absorbed and quickly metabolized in vivo into 
A771726, which is the active form of the drug. At its molecular level, leflunomide is a 
pyrimidine synthesis inhibitor that inhibits dihydroorotatedehydrogenase, an enzyme 
involved in the synthesis of pyrimidines. Unlike other cells during proliferation, 
lymphocytes increase their pool of pyrimidines much more than their increase in 
purines, therefore synthesizing them from both salvage and de novo pathways. By 
inhibiting dihydoorotatedehydrogenase, A771726 prevents the damaging lymphocytes 
from accumulating enough pyrimidines to support DNA synthesis, which is why 
leflunomide is considered an immunosuppressive agent.  
In addition to being a pyrimidine synthesis inhibitor, current research is being 
done to investigate A771726’s effect on inhibiting the over-expression ofCD147, 
thereby resulting in the down-regulation of matrix metalloproteinase-2 (MMP-2) and 
matrix metalloproteinase-9 (MMP-9) in active macrophages. CD147 is a member of 
the immunoglobulin superfamily, which consists of autoantibodies that are linked to 
autoimmune diseases such as rheumatoid arthritis. Pro-inflammatory cytokines, such 
as TNF, interleukin 1 and interleukin 17 are released in patients with rheumatoid 
arthritis and work synergistically to release matrix metalloproteinase-3’s (MMP3) 
from fibroblast-like synoviocytes and macrophages. MMP3’s are connected to 
pathologic tissue destruction, making them a vital interest to the research being done 
to find a cure for rheumatoid arthritis.  
Since CD147 is known to induce several MMP3’s and its expression levels 
have been found elevated in the synovial membranes of rheumatoid arthritis patients, 
research is being done that focuses on CD147 as a novel target in the treatment of 
rheumatoid arthritis. A study was done on phorbol myristate acetate differentiated 
THP-1 cells line, a monocyte-macrophage, to observe the effects of leflunomide’s 
active metabolite on CD147 levels. As MMP3’s are the major MMPs secreted by 
activated inflammatory macrophages and markers of progression of joint damage in 
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early rheumatoid arthritis, the effects of A771726 on MMP3 gelatinases were also 
evaluated in this study.  
In the macrophage cell model used in the study, an increased mRNA 
expression of MMP-2 and MMP-9 (both of which can be activated by MMP3) 
occurred in addition to the up-regulation of CD147, once the cells differentiated. The 
results found in the study showed that A771726 did not affect the mRNA expression 
of CD147, but did inhibit CD147 protein expression on the cell surface in a dosage 
dependent manner, which demonstrates that A771726 only has post-transcriptional 
effect on CD147 production in THP-1 cells. The authors go on to suggest that future 
studies should be conducted on the effect of A771726 on the glycosylation of CD147, 
since abnormal glycosylation was the cause of the instability of the CD147 proteins in 
their experiment. The study also showed that A771726 inhibited the induced increase 
of gelatinolytic activity of MMP-2 and MMP-9. The authors conclude by saying that 
their study indicates that A771726 inhibits the production of CD147 and the 
gelatinolytic activity of MMP-2 and MMP-9 in THP-1 cells, and they suggest that 
serum concentration of the metabolite should be monitored in rheumatoid arthritis 
patients so that sufficient concentration is maintained to allow the patient to achieve 
remission (Juang et al. 2011).  
Leflunomide can also be given as a combo-therapy. The thought of combining 
leflunomide with methotrexate as a double combination therapy was inspired by the 
idea that combining methotrexate with an agent whose mechanism of action was 
different than its own might produce better results than methotrexate monotherapy. In 
1999, a study was done on the safety and efficacy of treating active rheumatoid 
arthritis with a combination treatment of methotrexate and leflunomide. It was a 52-
week open-label study in which 30 patients who had active rheumatoid arthritis 
despite previous methotrexate treatment participated. Adverse effects and clinical 
response, as judged by the American College of Rheumatology 20% response criteria, 
were assessed as end point results. Of the patients, 53% met the ACR 20% response 
criteria and 2 patients met the ACR remission criteria after 1 year. While the study 
was only done on 30 patients and only a little more than half the patients met the ACR 
criteria, the study did introduce methotrexate and leflunomide combination therapy as 
a potential rheumatoid arthritis treatment (Mroczkowski et al. 1999). 
In 2004, another study was done on the safety and efficacy of the combination 
therapy of leflunomide with methotrexate. After a 24-week, randomized, double blind 
trial of taking leflunomide or a placebo with methotrexate, the patients could enter a 
24-week extension to continue the study. Results showed a 48-week maintained 
response to therapy for those patients who continued to receive leflunomide plus 
methotrexate. ACR 20% responder rates improved in the patients who switched from 
taking placebos to leflunomide. Similar ACR 20% response rates were found between 
patients who switched from placebo to leflunomide without a loading dose to those 
who received a randomized loading dose of leflunomide. However, fewer adverse 
events of diarrhea and nausea were found in those who did not receive the extra dose. 
In addition, patients who switched from placebo to leflunomide in the extension 
exhibited a lower incidence of elevated transaminases compared to the patients who 
were initially taking leflunomide throughout the 48-week trial, which may indicate 
possible hepatotoxicity caused by leflunomide (Kremer et al. 2004). While leflunomide 
might slow the progression of the disease, patients must discuss with their doctors 
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required monitoring and possible combination therapies that will yield the best 
efficacy/toxicity ratio while taking leflunomide.  
Besides for leflunomide and methotrexate, there are other synthetic DMARDs 
used to treat rheumatoid arthritis. Both sulfasalazine and hydroxychloroquine were 
initially developed for other disease like inflammatory bowel disease and malaria, but 
they were coincidentally found to be effective in rheumatoid arthritis. They are weak 
DMARDs, which is why they are usually only used as monotherapy in the early stages 
of rheumatoid arthritis or used in combination with other DMARDs such as 
methotrexate. With the use of hydroxychloroquine, ophthalmologic examinations are 
required every six to twelve months to detect color change or evidence of drug in the 
retina. Sulfasalazine, the most common used DMARD in Europe, is usually combined 
with methotrexate, hydroxychloroquine, or both. It is recommended that blood cell 
counts, especially white blood cell counts, be monitored in the first six months of 
taking sulfasalazine.  
Required monitoring while taking these drugs is evidence of how expensive and 
time-consuming DMARD treatments can be. This is why such an abundant amount of 
research is being done to find the most effective and convenient DMARD treatment 
against the autoimmune disease.  
A study was done to compare the efficacy of double or triple combination 
therapies involving methotrexate, sulfasalazine and hydroxychloroquine in patients 
with rheumatoid arthritis. Combinations of the different therapies were either 
methotrexate (MTX) with hydroxychloroquine (HCQ), MTX with sulfasalazine 
(SSZ), or the triple combination of MTX, HCQ and SSZ. One hundred seventy-one 
rheumatoid arthritis patients who were not previously treated with the medications 
were randomized to receive one of the three treatment combinations in this 2-year, 
double blind, and placebo controlled trial. The end point goal was to find the 
percentage of patients after 2 years who had a 20% response to their assigned therapy 
according to the American College of Rheumatology. While all combination treatments 
were well-tolerated, patients receiving the triple treatment responded best with 78% of 
them achieving the 20% ACR response required, compared to the 60% percent of 
those receiving MTX and HCQ and only 49% of those receiving MTX and SSZ 
(O’Dell et al. 2002). 
COMMONLY USED BIOLOGICAL DMARDS 
Pro-inflammatory cytokines, especially tumor necrosis factor-# and interleukin-
1, have vital roles in the pathophysiology of rheumatoid arthritis. This fact led to the 
development of biological agents that target TNF-# and interleukin-1 cytokines. In 
addition, recent research has been done that shows promise for therapies that block T-
cell co-stimulation and those that target B-cells. Since biological disease modifying 
anti-rheumatoid drugs have only recently been studied, and possible long-term adverse 
effects are still unknown, they are usually saved for use in combination therapies with 
other DMARDs such as methotrexate and leflunomide, for those rheumatoid arthritis 
patients who did not respond to synthetic DMARD monotherapy.  
DMARDs that are anti TNF-# agents include etanercept, infliximab, and 
adalimumab. Etanercept, a protein genetically engineered from a fusion gene, consists 
of two soluble TNF p75 receptor functional groups linked to the Fc portion of human 
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immunoglobulin-1. It binds to TNF-# molecules, thereby preventing the activation of 
the inflammatory cascade, in addition to inhibiting lymphotoxin-# (O’Dell 2007). 
A study was done on the efficacy of etanercept combination therapy with 
methotrexate, where 89 patients previously treated with methotrexate, who still 
showed signs of active rheumatoid arthritis symptoms, were randomly assigned to 
receive either etanercept or placebo subcutaneously, while continuing methotrexate 
therapy. At 24 weeks ACR response criteria was used to measure clinical response in 
improvements. Results showed that at 24 weeks 71% of the patients receiving 
etanercept-MTX combination therapy met the ACR 20% response criteria, compared 
to 27% of the group receiving placebo plus MTX. Thirty-nine percent of the 
etanercept group reached ACR 50% response criteria compared to the 3% of the 
placebo group. Significantly better outcomes, according to all measures of disease 
activity, were present in the patients receiving the etanercept-MTX combination 
therapy. Adverse effects associated with etanercept in this trial included only mild 
injection-site reactions, showing etanercept as a safe and potential combination therapy 
in patients with active rheumatoid arthritis who didn’t respond sufficiently enough to 
methotrexate therapy alone (Weinblatt et al. 1999). 
Infliximab is a 25% mouse and 75% human monoclonal antibody that bind to 
soluble and membrane bound TNF-# cytokines with high affinity, preventing them 
from interacting with their receptors, resulting in the down-regulation of macrophage 
and T cell function.  
Adalimumab is a recombinant human anti-TNF antibody. By combining with 
TNF-#, it prevents its interaction with its p77 and p75 cell surface receptors, resulting 
in the down-regulation of macrophage and T-cell function, which is similar to 
infliximab’s mechanism of action (Furst et al. 2009). A 24-week, randomized, double-
blind, placebo-controlled study was done in 2002 to test the efficacy and safety of 
adalimumab in combination with MTX given to patients with active rheumatoid 
arthritis who have not responded adequately to previous MTX mono treatment. The 
results showed that an ACR 20%, 50% and 70% response were all achieved by a 
significantly greater proportion of patients in the adalimumab plus MTX administered 
group than in the groups given placebos with MTX. The greater the dose of 
adalimumab was given, increasing from 20-mg to 40-mg, to 80-mg, respectively, the 
higher the response rate appeared. Response seemed rapid, as the greatest proportion 
of adalimumab-treated patients achieving an ACR 20% response occurred at the first 
scheduled visit of one week. Adverse events were similar in both control groups, 
indicating that adalimumab was well tolerated (Weinblatt et al. 2003).  
While this clinical trial did demonstrate that adalimumab with combined MTX 
therapy has been effective in reducing signs and symptoms of active rheumatoid 
arthritis, and does give hope for potential combination therapy, the study was only 
held for 24 weeks. While this might be sufficient to show improvements caused by 
adalimumab in rheumatoid arthritis symptoms, it does not show how effective 
adalimumab is in the long run at stopping the progression of the disease, or pushing 
the patient into remission (Kremer et al. 2008). 
Abatacept, a recombinant protein, acts by blocking T-cell co-stimulation and 
preventing the autoimmune response caused by rheumatoid arthritis. A study was 
done on 652 patients who had active rheumatoid arthritis, despite previously being 
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treated with methotrexate, to see the efficacy of abatacept. 433 patients were randomly 
assigned to be given an infusion of a fixed dose of abatacept once a month, while 219 
received placebos. Results showed at one year, progression of structural joint damage 
was statistically slowed by abatacept. Physical function significantly improved in 
63.7% of the patients. While these results seem to be very promising for abatacept 
therapy, the study only involved 1 group of patients over 1 year and therefore is very 
limited in its evidence of the efficacy of the drug. Longer treatment in different 
populations is needed to establish its effectiveness against the progression of 
rheumatoid arthritis (Kremer et al. 2008).  
Rituximab is a genetically engineered humanized mouse monoclonal antibody 
that works against CD20 molecules on the B-cell surfaces, thereby depleting the B-
cells, stopping their immune response and thereby reducing inflammation (Furst et al. 
2009). The advantage of rituximab is that it works on B-cells rather than inhibiting 
TNF cytokines, which is a relief to patients who do not benefit from anti-TNF agents, 
either at the start of treatment or after receiving some treatment. A study was done in 
Finland to examine the effectiveness of rituximab on rheumatoid arthritis patients who 
failed to respond to TNF antagonists, or had a contraindication to these drugs. Data 
was collected from five rheumatology clinics and examined 81 patients in total who 
were treated with rituximab from April 2005 to June 2008, since previous therapies 
were unsuccessful in reaching adequate responses. Treatment response was defined 
according to EULAR response criteria and disease activity score using 28 joint counts 
(DAS28). The results of the trial showed adequate EULAR response in 77% of the 
patients and a suppressed DAS28 score of 2.08 units. Since the percentage of good 
responses of patients taking DMARDs other than methotrexate with rituximab, was 
somewhat higher than those taking methotrexate alone with rituximab, it’s obvious 
that rituximab is equally effective when combined with methotrexate and other 
DMARDs. The study concludes that rituximab was effective in controlling disease 
activity in patients who did not show adequate results taking other DMARDs alone 
(Valleala et al. 2009). 
Tocilizumab is the first of its kind as an anti-interleukin 6 receptor monoclonal 
antibody. Interleukin 6, a pro-inflammatory cytokine that is released by immune, 
endothelial and synovial cells, induces osteoclast differentiation, therefore contributing 
to the joint and bone destruction occurring in rheumatoid arthritis patients.  The drug 
is typically given with or without methotrexate, for patients who did not respond to 
single or multiple anti-TNF therapies. Similarly to those associated with other 
monoclonal immune suppressors, adverse effects include infusion reactions, 
development of neutralizing antibodies, hypersensitivity reactions, and increased risk 
of serious infection (Murri 2010).  
Studies done on rheumatoid arthritis patients who took tocilizumab with 
methotrexate revealed positive results. One study was done on 499 patients who had 
an inadequate response to one or more anti-TNF agents. Results after the 24 weeks 
showed that 50.0% of those who received 8mg of tocilizumab achieved ACR 20% 
response criteria, compared to the 30.4% in the 4mg group and the 10.1% in the 
placebo group. At week four, ACR 20% response criteria was reached by more 
patients receiving 8mg of tocilizumab than those in the control groups, as was DAS28 
remission rates achieved at week 24. The most common adverse events reported in the 
trial were infections, gastrointestinal symptoms, rash and headaches; however, most 
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were mild and moderate. This study demonstrates the potential benefit of tocilizumab 
given with methotrexate as an effective therapy against rheumatoid arthritis  (Emery 
et al 2008). Results showed rapid and sustained improvements of rheumatoid arthritis 
symptoms for those who failed to respond well to TNF antagonists and reported mild 
adverse effects.  
Even though the biological DMARDs mentioned above did show promising 
trial results when given with methotrexate, biological DMARDs are so fresh and new 
in research that efficacy and adverse effects are unable to be studied in the long run. 
Most of these trials are over a 1 to 2 year period, which is not an adequate amount of 
time to measure achievable long-term remission induced by these therapies. While they 
definitely show great potential in slowing down the progression of bone destruction 
and active symptoms caused by rheumatoid arthritis, more research and long-term 
studies must be done to evaluate the lasting effects and possible negative side effects of 
these young progressing therapies. 
ADVERSE EFFECTS AND DISADVANTAGES  
Potential increased risk of serious infection is one of the major side effects of 
biological DMARDs. TNF inhibitors in particular have been noticed to increase the 
risk of developing reactivation of dormant tuberculosis. This is why it is important for 
a patient who is about to start on anti-TNF agents to undergo tuberculin skin testing 
and even chest radiographs, if needed. A national prospective observational study was 
done on data collected from the British Society for Rheumatology Biologics Register 
(BSRBR) to test if different anti-TNF agents increase the risk of tuberculosis 
reactivity. A comparison of TB rates in 10712 patients who were either treated with 
etanercept, infliximab, or adalimumab showed three-to four-fold higher TB rates in 
patients taking infliximab and adalimumab, than those receiving etanercept (Dixon et 
al. 2010). 
Another prospective observational study was done from the BSRBR, where 
11,881 patients treated with anti-TNF agents were evaluated to research an increased 
risk of septic arthritis. While the results did not show that anti-TNF therapy was a 
significant cause of Septic Arthritis, they did find that it was associated with doubling 
the risk of developing SA.  
Both studies were done on an enormous number of subjects who might have 
had different contributing factors in developing tuberculosis or septic arthritis 
(Galloway et al. 2011). While these studies do not positively prove that anti-TNF 
agents used in rheumatoid arthritis patients increase the risk of infection and 
tuberculosis, they do show a probable basis for the fact that TNF inhibitors might 
contribute to these risks. For this reason, physicians and surgeons should be aware of 
these potentially life-threatening complications, and instruct their patients on how to 
manage and prevent these adverse outcomes.  
The cost of DMARDs and the necessary monitoring required while being 
treated with these drugs can be extremely expensive and burdensome, especially for 
elderly patients with severe rheumatoid arthritis. A large amount of monitoring is 
needed while on DMARD treatment, since complications such as infection and 
toxicity can occur. Tests such as CBCs and platelet counts are necessary periodically 
to rule out infection, and yearly ophthalmologic tests are needed for patients on 
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hydroxychloroquine. All in all, sometimes the excessive expense and adverse effects 
might prevent patients from benefiting from these new and promising treatments. 
CONCLUSION 
Rheumatoid arthritis can be a crippling and incapacitating disease, if left 
untreated. Disease modifying anti-rheumatic drugs work in the unconventional way of 
modifying the disease and inhibiting the underlying cause of inflammation present in 
rheumatoid arthritis, in order to reach sustainable remission. While it is a relatively 
new group of drugs, an abundant amount of research and effort has been put in to find 
the most suitable and effective treatment when using these agents. From the studies 
mentioned above, it is obvious that DMARDs has a tremendous potential of becoming 
the leading treatment in autoimmune inflammatory disease, such as rheumatoid 
arthritis. According to Tak et al. (2011), the complex and varied mechanism of actions 
of these drugs make it necessary for researchers to study the different mechanism and 
contemplate which combinations are effective and safe. What’s more, rheumatologists 
should put effort in predicting clinical responses of individual patients who they 
prescribe DMARDs to. By doing so, the physician may very possibly maximize the 
patient’s outcome, minimize safety concerns and reduce treatment costs caused by 
complications (Tak et al. 2011). Even though there is a long way to go, DMARDs are 
thriving at helping people overcome rheumatoid arthritis, and show great potential in 
some day reaching the ultimate goal of causing rheumatoid arthritis patients to go into 
permanent remission, thus becoming the cure for rheumatoid arthritis.  
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